Mankind Pharma FY25: Strong Growth & Expansion

  Published 10 months ago

Mankind Pharma reported strong Q4 FY25 results with 27.19% revenue growth to Rs 3,079.37 crore, despite a 9.87% drop in profit before tax. Export revenue doubled, fueled by new launches and BSV consolidation with strategic initiatives underway for long term growth.

  • Revenue up 27.19% YoY to Rs 3,079.37 crore.
  • Export revenue doubled, driven by BSV & launches.
  • Focus on chronic, OTC, & BSV portfolios for growth.

You might like these

Kanungo Joins IIFL Board: RBI Expert Boosts Financial Leadership

MCX Slips Amid Technical Glitch

Tata Communications Outperform Rating & Growth Outlook

India Slams US Tariffs on Russian Oil Trade

Mahindra Sales Jump 26% in July

Trump Backs Nippon Steel's U.S. Steel Bid

Greaves Cotton Q1 PBT Soars 185%

News that matters the most ⚡